SG11201407220YA - N-alkyltriazole compounds as lpar antagonists - Google Patents
N-alkyltriazole compounds as lpar antagonistsInfo
- Publication number
- SG11201407220YA SG11201407220YA SG11201407220YA SG11201407220YA SG11201407220YA SG 11201407220Y A SG11201407220Y A SG 11201407220YA SG 11201407220Y A SG11201407220Y A SG 11201407220YA SG 11201407220Y A SG11201407220Y A SG 11201407220YA SG 11201407220Y A SG11201407220Y A SG 11201407220YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- new jersey
- compounds
- drive
- designated states
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000005557 antagonist Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 abstract 1
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 abstract 1
- 241000867614 Mimus polyglottos Species 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661961P | 2012-06-20 | 2012-06-20 | |
| PCT/EP2013/062461 WO2013189864A1 (en) | 2012-06-20 | 2013-06-17 | N-alkyltriazole compounds as lpar antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407220YA true SG11201407220YA (en) | 2014-12-30 |
Family
ID=48628667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407220YA SG11201407220YA (en) | 2012-06-20 | 2013-06-17 | N-alkyltriazole compounds as lpar antagonists |
Country Status (22)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014003499A2 (pt) | 2011-08-15 | 2017-06-13 | Intermune Inc | compostos ou sais farmaceuticamente aceitáveis dos mesmos e composições farmacêuticas e respectivos usos de quantidades eficazes e métodos para tratar, prevenir, reverter, parar ou retardar a prograssão de doença ou condição selecionada de fibrose, câncer ou distúrbios respiratórios e modular a atividade de receptor em célula |
| MX2014014711A (es) * | 2012-06-20 | 2015-03-04 | Hoffmann La Roche | Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar). |
| AU2014232383B2 (en) | 2013-03-15 | 2019-01-17 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| EP3162801B1 (en) | 2014-06-27 | 2020-07-22 | UBE Industries, Ltd. | Salt of halogen-substituted heterocyclic compound |
| AR108838A1 (es) * | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| CN111479807B (zh) * | 2017-12-19 | 2024-11-26 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸异噁唑吖嗪 |
| JP7208240B2 (ja) * | 2017-12-19 | 2023-01-18 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸トリアゾールアジン |
| KR20200100713A (ko) | 2017-12-19 | 2020-08-26 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 트리아졸 아졸 |
| KR102725744B1 (ko) * | 2017-12-19 | 2024-11-01 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 피라졸 아진 |
| ES2942767T3 (es) | 2017-12-19 | 2023-06-06 | Bristol Myers Squibb Co | Isoxazol azoles del ácido ciclohexílico como antagonistas del LPA |
| CN112041029B (zh) | 2017-12-19 | 2025-01-24 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸吡唑唑类 |
| ES2962367T3 (es) | 2017-12-19 | 2024-03-18 | Bristol Myers Squibb Co | Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA) |
| CN112041304B (zh) | 2017-12-19 | 2025-03-07 | 百时美施贵宝公司 | 作为lpa拮抗剂的异噁唑n-连接的氨基甲酰基环己基酸 |
| DK3710438T3 (da) | 2017-12-19 | 2021-12-06 | Bristol Myers Squibb Co | Triazol n-bundne carbamoylcyclohexylsyrer som lpa-antagonister |
| US11180488B2 (en) | 2017-12-19 | 2021-11-23 | Bristol-Myers Squibb Company | Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists |
| CN112041302B (zh) | 2017-12-19 | 2024-11-19 | 百时美施贵宝公司 | 作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸 |
| WO2019133770A2 (en) * | 2017-12-29 | 2019-07-04 | Biomarin Pharmaceutical Inc. | Glycolate oxidase inhibitors for the treatment of disease |
| US12209072B2 (en) | 2018-09-18 | 2025-01-28 | Bristol-Myers Squibb Company | Cyclopentyl acids as LPA antagonists |
| KR102800284B1 (ko) * | 2018-09-18 | 2025-04-23 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헵틸 산 |
| ES2941774T3 (es) * | 2018-09-18 | 2023-05-25 | Bristol Myers Squibb Co | Acidos oxabiciclo como antagonistas de LPA |
| JP7431961B2 (ja) * | 2019-11-15 | 2024-02-15 | ギリアード サイエンシーズ， インコーポレイテッド | Ｌｐａ受容体アンタゴニストとしてのトリアゾールカルバメートピリジルスルホンアミド及びその使用 |
| US11702407B2 (en) | 2020-06-03 | 2023-07-18 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| EP4337641A1 (en) | 2021-05-11 | 2024-03-20 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| US20220411406A1 (en) * | 2021-05-13 | 2022-12-29 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| EP4444707A1 (en) | 2021-12-08 | 2024-10-16 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| TW202342017A (zh) | 2022-02-25 | 2023-11-01 | 美商洛子峰生物有限公司 | 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| GB2466121B (en) * | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) * | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| US20110065695A1 (en) | 2009-09-11 | 2011-03-17 | Jeremy Beauchamp | Use of aminodihydrothiazines for the treatment or prevention of diabetes |
| GB2474748B (en) * | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| WO2011159550A2 (en) | 2010-06-14 | 2011-12-22 | Amidra Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist and uses thereof |
| WO2011159633A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Inhalable formulations of lysophosphatdic acid receptor antagonists |
| BR112013014019A2 (pt) * | 2010-12-07 | 2016-09-13 | Amira Pharmaceuticals Inc | antagonistas do receptor do ácido lisofosfatídico e seus usos |
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| BR112014003499A2 (pt) | 2011-08-15 | 2017-06-13 | Intermune Inc | compostos ou sais farmaceuticamente aceitáveis dos mesmos e composições farmacêuticas e respectivos usos de quantidades eficazes e métodos para tratar, prevenir, reverter, parar ou retardar a prograssão de doença ou condição selecionada de fibrose, câncer ou distúrbios respiratórios e modular a atividade de receptor em célula |
-
2013
- 2013-06-17 BR BR112014030685A patent/BR112014030685A2/pt not_active Application Discontinuation
- 2013-06-17 CA CA2869541A patent/CA2869541A1/en not_active Abandoned
- 2013-06-17 IN IN9348DEN2014 patent/IN2014DN09348A/en unknown
- 2013-06-17 JP JP2015517704A patent/JP2015520202A/ja not_active Ceased
- 2013-06-17 UA UAA201500428A patent/UA109868C2/ru unknown
- 2013-06-17 PE PE2014002232A patent/PE20142448A1/es not_active Application Discontinuation
- 2013-06-17 AU AU2013279512A patent/AU2013279512A1/en not_active Abandoned
- 2013-06-17 MA MA37764A patent/MA37764A1/fr unknown
- 2013-06-17 US US14/401,009 patent/US9321738B2/en not_active Expired - Fee Related
- 2013-06-17 KR KR1020147035768A patent/KR20150021057A/ko not_active Ceased
- 2013-06-17 HK HK15106927.8A patent/HK1206342A1/xx unknown
- 2013-06-17 EP EP13729330.4A patent/EP2864300A1/en not_active Withdrawn
- 2013-06-17 MX MX2014014710A patent/MX2014014710A/es unknown
- 2013-06-17 CN CN201380032285.0A patent/CN104411692A/zh active Pending
- 2013-06-17 WO PCT/EP2013/062461 patent/WO2013189864A1/en active Application Filing
- 2013-06-17 SG SG11201407220YA patent/SG11201407220YA/en unknown
- 2013-06-17 EA EA201492285A patent/EA201492285A1/ru unknown
-
2014
- 2014-11-17 CR CR20140525A patent/CR20140525A/es unknown
- 2014-11-21 CO CO14256136A patent/CO7131358A2/es unknown
- 2014-11-28 CL CL2014003243A patent/CL2014003243A1/es unknown
- 2014-12-04 IL IL236088A patent/IL236088A0/en unknown
- 2014-12-15 PH PH12014502789A patent/PH12014502789A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20150133511A1 (en) | 2015-05-14 |
| MA37764A1 (fr) | 2016-01-29 |
| CR20140525A (es) | 2015-01-12 |
| EP2864300A1 (en) | 2015-04-29 |
| CL2014003243A1 (es) | 2015-03-20 |
| IL236088A0 (en) | 2015-02-01 |
| PE20142448A1 (es) | 2015-01-28 |
| CN104411692A (zh) | 2015-03-11 |
| WO2013189864A1 (en) | 2013-12-27 |
| EA201492285A1 (ru) | 2015-04-30 |
| US9321738B2 (en) | 2016-04-26 |
| KR20150021057A (ko) | 2015-02-27 |
| JP2015520202A (ja) | 2015-07-16 |
| PH12014502789A1 (en) | 2015-02-09 |
| CO7131358A2 (es) | 2014-12-01 |
| CA2869541A1 (en) | 2013-12-27 |
| HK1206342A1 (en) | 2016-01-08 |
| AU2013279512A1 (en) | 2014-10-16 |
| UA109868C2 (ru) | 2015-10-12 |
| BR112014030685A2 (pt) | 2017-06-27 |
| IN2014DN09348A (enrdf_load_stackoverflow) | 2015-07-17 |
| MX2014014710A (es) | 2015-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
| SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
| SG11201407229UA (en) | Substituted pyrazole compounds as lpar antagonists | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201908560SA (en) | Heterocyclic compounds useful as dual atx/ca inhibitors | |
| SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201408261UA (en) | Syringe | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201406973PA (en) | Complement pathway modulators and uses thereof | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11201806424TA (en) | Therapeutic compounds |